In last trading session, Neumora Therapeutics Inc (NASDAQ:NMRA) saw 1.31 million shares changing hands with its beta currently measuring 1.99. Company’s recent per share price level of $1.38 trading at -$0.05 or -3.50% at ring of the bell on the day assigns it a market valuation of $223.53M. That closing price of NMRA’s stock is at a discount of -1248.55% from its 52-week high price of $18.61 and is indicating a premium of 8.7% from its 52-week low price of $1.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.27 million shares which gives us an average trading volume of 3.28 million if we extend that period to 3-months.
For Neumora Therapeutics Inc (NMRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.11. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.38 in the current quarter.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Upright in the red during last session for losing -3.50%, in the last five days NMRA remained trading in the red while hitting it’s week-highest on Thursday, 03/06/25 when the stock touched $1.38 price level, adding 10.35% to its value on the day. Neumora Therapeutics Inc’s shares saw a change of -86.98% in year-to-date performance and have moved -3.50% in past 5-day. Neumora Therapeutics Inc (NASDAQ:NMRA) showed a performance of -22.47% in past 30-days. Number of shares sold short was 12.28 million shares which calculate 7.25 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 54.0% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -44.93% in reaching the projected high whereas dropping to the targeted low would mean a loss of -44.93% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 4.29% while estimates for its earnings growth in next 5 years are of 8.30%.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Insiders are in possession of 27.52% of company’s total shares while institution are holding 71.99 percent of that, with stock having share float percentage of 99.32%. Investors also watch the number of corporate investors in a company very closely, which is 71.99% institutions for Neumora Therapeutics Inc that are currently holding shares of the company. SOFTBANK GROUP CORP. is the top institutional holder at NMRA for having 7.65 million shares of worth $75.17 million. And as of 2024-06-30, it was holding 4.8099 of the company’s outstanding shares.
The second largest institutional holder is T. ROWE PRICE INVESTMENT MANAGEMENT, INC., which was holding about 5.1 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.2086 of outstanding shares, having a total worth of $50.14 million.
